# Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy

> **NCT06914050** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Lung Cancer, Small Cell
- Limited-stage Small Cell Lung Cancer (LS-SCLC)

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** EC/EP
- **RADIATION:** SBRT
- **RADIATION:** Chest radiotherapy

## Key facts

- **NCT ID:** NCT06914050
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04
- **Primary completion:** 2026-04
- **Final completion:** 2028-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06914050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06914050, "Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06914050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*